7 • 2018 ASCRS Clinical Survey
Most respondents (60%) do not perform corneal collagen
crosslinking and have no plans to do so within the next
year. U.S. respondents were more likely to take this latter
stance (76% compared to 31%). Only 14% of U.S. oph-
thalmologists are performing crosslinking. Those who are
performing this procedure are doing so to treat keratoco-
nus with smaller numbers treating post-refractive ectasia
or combining it with a refractive procedure.
"The reimbursement pathway in the U.S. has made
it hard for clinicians to incorporate crosslinking into
their practice, despite this being a vitally important
procedure to help those with advancing keratoco-
nus. Perhaps changes in the insurance landscape
and reduction in cost of drugs required to perform
the treatment will allow more clinicians to offer this
treatment."
—Preeya Gupta, MD
ASCRS Cornea Clinical Committee
Are you currently performing corneal collagen crosslinking?
• Overall, nearly 60% of respondents have no plans to perform crosslinking procedures, 59%
• U.S. respondents are more than twice the rate of Non-U.S. respondents, 76% to 31%
• 55% of Non-U.S. respondents are currently performing
• Only 14% of U.S. respondents
n=467
88
Which factor do you primarily use to determine suitability for corneal collagen crosslinking?
• Overall
• Change in topography: 39%
• Progression of Kmax: 32%
• Change in tomography: 19%
n=135
90
Which of the following conditions are you treating with corneal collagen crosslinking?
• Overall, 90% Keratoconus
n=136
91
Ocular surface/cornea
